PDL BioPharma Inc. (PDLI)

3.59
NASDAQ : Health Technology
Prev Close 3.79
Day Low/High 3.59 / 3.79
52 Wk Low/High 2.25 / 3.82
Avg Volume 1.64M
Exchange NASDAQ
Shares Outstanding 128.11M
Market Cap 485.53M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

PDL BioPharma To Announce 2018 Fourth Quarter And Full Year Financial Results On March 14, 2019

PDL BioPharma To Announce 2018 Fourth Quarter And Full Year Financial Results On March 14, 2019

INCLINE VILLAGE, Nev., March 7, 2019 /PRNewswire/ -- PDL BioPharma, Inc.

PDL BioPharma To Participate At Cowen 39th Annual Health Care Conference

PDL BioPharma To Participate At Cowen 39th Annual Health Care Conference

INCLINE VILLAGE, Nev., March 5, 2019 /PRNewswire/ -- PDL BioPharma, Inc.

PDL BioPharma Announces Launch Of An Authorized Generic Of Tekturna® (aliskiren) In Partnership With Prasco Laboratories

PDL BioPharma Announces Launch Of An Authorized Generic Of Tekturna® (aliskiren) In Partnership With Prasco Laboratories

INCLINE VILLAGE, Nev., March 4, 2019 /PRNewswire/ -- PDL BioPharma, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXE, CTLT, FTI, INSW, LAZ, MAS, MLI, NCLH, PCMI, PDLI, TTWO, UFS, VIAV Downgrades: CIA, DLR, I, LIVE, MKL, SNHY Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

First Week Of PDLI August 16th Options Trading

First Week Of PDLI August 16th Options Trading

Investors in PDL BioPharma Inc saw new options become available this week, for the August 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 224 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

PDL BioPharma To Present At The 30th Annual Piper Jaffray Healthcare Conference

PDL BioPharma To Present At The 30th Annual Piper Jaffray Healthcare Conference

INCLINE VILLAGE, Nev., Nov.

PDL BioPharma Reports Third Quarter 2018 Financial Results

PDL BioPharma Reports Third Quarter 2018 Financial Results

Announces CEO succession plan

PDL BioPharma To Announce Third Quarter Financial Results On November 6, 2018

PDL BioPharma To Announce Third Quarter Financial Results On November 6, 2018

INCLINE VILLAGE, Nev., Oct.

PDL BioPharma Names Edward Imbrogno Vice President Of Finance

PDL BioPharma Names Edward Imbrogno Vice President Of Finance

INCLINE VILLAGE, Nev., Oct.

Analyst Favorites With Strong Buyback Activity: PDL BioPharma Ranks As A Top Pick

Analyst Favorites With Strong Buyback Activity: PDL BioPharma Ranks As A Top Pick

A study of analyst recommendations at the major brokerages shows that PDL BioPharma Inc is the #109 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ASPS, BMRN, CNHI, GTIM, JHX, NXEOU, PICO, USAP, VTSI, WUBA Downgrades: ABCB, CTRP, FDP, GBLI, MHLD, PDLI, SMCI, TV Initiations: BHF, PLXP Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CF, HF, ICL, NGS, PDLI, PFMT, PMBC, RGCO, UONE, UONEK Downgrades: HSKA, HY, PRA, SPH Initiations: BNTC, VST Read on to get TheStreet Quant Ratings' detailed report:

Richard L. Lindstrom, M.D. Joins LENSAR, Inc. Board Of Directors

Richard L. Lindstrom, M.D. Joins LENSAR, Inc. Board Of Directors

LENSAR, Inc., an emerging leader in next generation femtosecond laser technology for refractive cataract surgery, today is pleased to announce world renowned ophthalmologist Richard L.

Neos Therapeutics Stock Soars on 3rd Unsolicited Buyout Offer From PDL BioPharma

Neos Therapeutics Stock Soars on 3rd Unsolicited Buyout Offer From PDL BioPharma

Pharmaceutical company Neos received an offer for $10.25 per share, which would value the deal around $288 million. It's the third time PDL has tried to make a deal.

LENSAR® Receives FDA Clearances For Laser Cataract Platform Integration With OCULUS Pentacam® Tomographers

LENSAR, Inc., a global leader in next generation femtosecond laser technology for refractive cataract surgery, today announced it received 510(k) clearance for integration of the popular OCULUS Pentacam® (both...

Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers

Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers

Sarepta Therapeutics, Paratek Pharmaceuticals and PDL BioPharma were among the biotech stock movers in premarket trading on Monday.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CPLP, IRDM Downgrades: GPT, MBI, PDLI, PWOD, TLRD Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Argos Plummets 72%, Leads Biotech Movers

Argos Plummets 72%, Leads Biotech Movers

Also falling was Global Blood Therapeutics.

Short Interest Increases 29.7% For PDLI

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 2,792,771 share increase in total short interest for PDL BioPharma Inc , to 12,191,416, an increase of 29.71% since 01/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

LENSAR® Launches Streamline™ III To Assist Cataract Surgeons In Managing And Improving Astigmatism Treatment For Optimal Visual Outcomes

LENSAR® Launches Streamline™ III To Assist Cataract Surgeons In Managing And Improving Astigmatism Treatment For Optimal Visual Outcomes

LENSAR, Inc., a global leader in next generation femtosecond laser technology for refractive cataract surgery, today announced Streamline III, its third system upgrade in less than two years.

PDL BioPharma Stock Sees Short Interest Decline 14.5%

PDL BioPharma Stock Sees Short Interest Decline 14.5%

The most recent short interest data has been released for the 11/15/2016 settlement date, which shows a 999,222 share decrease in total short interest for PDL BioPharma Inc , to 5,892,922, a decrease of 14.50% since 10/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

In a few weeks, investors will know if Lilly's solanezumab is a groundbreaking treatment for Alzheimer's or another drug casualty to a disease that has eluded pharmaceutical companies for years.

Short Interest In PDL BioPharma Declines 14.2%

Short Interest In PDL BioPharma Declines 14.2%

The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 1,140,664 share decrease in total short interest for PDL BioPharma Inc , to 6,915,394, a decrease of 14.16% since 08/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Short Interest Moves 28% Lower For PDLI

Short Interest Moves 28% Lower For PDLI

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 3,055,374 share decrease in total short interest for PDL BioPharma Inc , to 7,833,748, a decrease of 28.06% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

PDL BioPharma (PDLI) Stock Plummets on Q2 Revenue Miss

PDL BioPharma (PDLI) Stock Plummets on Q2 Revenue Miss

Following Thursday's closing bell, PDL BioPharma (PDLI) reported lower-than-expected revenue for the 2016 second quarter.

Dividend Action Aplenty This Week

Earnings season is often a busy period for dividend hikes and cuts, and this one has been no exception.

Today's Weak On High Volume Stock: PDL BioPharma (PDLI)

Today's Weak On High Volume Stock: PDL BioPharma (PDLI)

Trade-Ideas LLC identified PDL BioPharma (PDLI) as a weak on high relative volume candidate

TheStreet Quant Rating: C- (Hold)